NCT01352273View on ClinicalTrials.gov

MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Advanced Solid Tumors
Interventions
DRUG

MEK162 + RAF265

Trial Locations (8)

8091

Pfizer Investigative Site, Zurich

28050

Pfizer Investigative Site, Madrid

33612

H. Lee Moffitt Cancer Center & Research Institute Moffitt 4, Tampa

84103

University of Utah / Huntsman Cancer Institute Huntman 2, Salt Lake City

97239

Oregon Health & Science University OHSU 3, Portland

T6G 1Z2

Pfizer Investigative Site, Edmonton

H3T 1E3

Pfizer Investigative Site, Montreal

NO-0379

Pfizer Investigative Site, Oslo

All Listed Sponsors
lead

Array Biopharma, now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT01352273 - MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations | Biotech Hunter | Biotech Hunter